Tango Therapeutics Appoints Experienced Biopharma CFO Sung Lee to Board of Directors

summarizeSummary

Tango Therapeutics appointed Sung H. Lee, an experienced biopharma finance executive, to its Board of Directors, enhancing the board's financial and strategic expertise.

check_boxKey Events

• Board Expansion and New Director

  The Board of Directors increased its size to eight and appointed Sung H. Lee as a new independent Class I director, effective January 2, 2026.

• Sung Lee's Extensive Experience

  Mr. Lee brings over 20 years of finance leadership, currently serving as EVP and CFO at Cytokinetics, with prior CFO roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics, and 14 years at Gilead Sciences.

• Director Compensation

  Mr. Lee will receive a stock option to purchase 60,000 shares at an exercise price of $8.93, a restricted stock unit award for 10,000 shares, and an annual retainer of $40,000.

auto_awesomeAnalysis

The appointment of Sung H. Lee, a seasoned finance executive with over two decades of experience in the biopharmaceutical and technology sectors, significantly strengthens Tango Therapeutics' Board of Directors. His background as CFO at multiple biotech companies and his tenure at Gilead Sciences will be invaluable as Tango advances its lead program, vopimetostat, into registrational studies and scales its organization for late-stage clinical development. This move enhances the company's financial and strategic oversight.